218 Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, et al. Inflammation drives dysbiosis and bacterial invasion inmurine models of ileal Crohn’s disease. PLoS One 2012;7(7):e41594. doi: 10.1371/ journal.pone.0041594. Schaubeck M, Clavel T, Calasan J, Lagkouvardos I, Haange SB, Jehmlich N, et al. Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence. Gut 2016;65(2):225-37. doi: 10.1136/gutjnl-2015-309333. Kaakoush NO. Insights into the Role of Erysipelotrichaceae in the Human Host. Front Cell Infect Microbiol 2015;5:84. doi: 10.3389/fcimb.2015.00084. van Haaften WT, Blokzijl T, Hofker HS, Olinga P, Dijkstra G, Bank RA, et al. Intestinal stenosis in Crohn’s disease shows a generalized upregulation of genes involved in collagenmetabolismand recognition that could serve as novel anti-fibrotic drug targets. Therap Adv Gastroenterol 2020;13:1756284820952578. doi: 10.1177/1756284820952578. Carstens A, Dicksved J, Nelson R, Lindqvist MM, Andreasson A, Bohr J, et al. The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis. Clin Transl Gastroenterol 2019;10(7):e00065. doi: 10.14309/ctg.0000000000000065. Nielsen S, Needham B, Leach ST, Day AS, Jaffe A, Thomas T, et al. Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Sci Rep 2016;6:24857. doi: 10.1038/srep24857. Vernocchi P, Del Chierico F, Russo A, Majo F, Rossitto M, Valerio M, et al. Gut microbiota signatures in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. PLoS One 2018;13(12):e0208171. doi: 10.1371/journal.pone.0208171. Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, et al. Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. Sci Rep 2019;9(1):18593. doi: 10.1038/ s41598-019-55028-7. Cavallari JF, Pokrajac NT, Zlitni S, Foley KP, Henriksbo BD, Schertzer JD. NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice. Am J Physiol Endocrinol Metab 2020;319(2):E305-E314. doi: 10.1152/ajpendo.00181.2020. Ha CWY, Martin A, Sepich-Poore GD, Shi B, Wang Y, Gouin K, et al. Translocation of Viable Gut Microbiota to Mesenteric Adipose Drives Formation of Creeping Fat in Humans. Cell 2020;183(3):666-683.e17. doi: 10.1016/j.cell.2020.09.009. Zhuang X, Tian Z, Li N, Mao R, Li X, Zhao M, et al. Gut Microbiota Profiles and Microbial-Based Therapies in Post-operative Crohn’s Disease: A Systematic Review. Front Med (Lausanne) 2021;7:615858. doi: 10.3389/ fmed.2020.615858. Frau A, Ijaz UZ, Slater R, Jonkers D, Penders J, Campbell BJ, et al. Inter-kingdom relationships in Crohn’s disease explored using a multi-omics approach. Gut Microbes 2021;13(1):1930871. doi: 10.1080/19490976.2021.1930871. Davrandi M, Harris S, Smith PJ, Murray CD, Lowe DM. The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder. J Clin Immunol 2022;42:312-324. doi: 10.1007/s10875-021-01165-6. Liang JQ, Li T, Nakatsu G, Chen YX, Yau TO, Chu E, et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut 2020;69(7):1248-1257. doi: 10.1136/ gutjnl-2019-318532. Zhao L, Cho WC, Nicolls MR. Colorectal Cancer-Associated Microbiome Patterns and Signatures. Front Genet 2021;12:787176. doi: 10.3389/fgene.2021.787176. Zhou Y, Chen L, Sun G, Li Y, Huang R. Alterations in the gut microbiota of patients with silica-induced pulmonary fibrosis. J Occup Med Toxicol 2019;14:5. doi: 10.1186/s12995-019-0225-1. Chapter 6 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66
RkJQdWJsaXNoZXIy MjY0ODMw